dc.contributor |
Казанский федеральный университет |
|
dc.contributor.author |
Gaysina Leylya Rafaelevna |
|
dc.contributor.author |
Bain Stephen |
|
dc.contributor.author |
Bode Bruce |
|
dc.contributor.author |
Clausen Jesper Ole |
|
dc.contributor.author |
Coppieters Ken |
|
dc.contributor.author |
Gumprecht Janusz |
|
dc.contributor.author |
Hansen Troels Krarup |
|
dc.contributor.author |
von Herrath Matthias |
|
dc.contributor.author |
Mathieu Chantal |
|
dc.contributor.author |
Morales Cristobal |
|
dc.contributor.author |
Mosenzon Ofri |
|
dc.contributor.author |
Segel Stine |
|
dc.contributor.author |
Tsoukas George |
|
dc.contributor.author |
Pieber Thomas R |
|
dc.date.accessioned |
2021-04-09T07:42:36Z |
|
dc.date.available |
2021-04-09T07:42:36Z |
|
dc.date.issued |
2021 |
|
dc.identifier.citation |
Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial / von Herrath M. [at al.] // Lancet Diabetes Endrocrinol. - 2021. - Vol. 9, Is. 4. - P. 212-224. |
|
dc.identifier.uri |
https://dspace.kpfu.ru/xmlui/handle/net/163520 |
|
dc.description.abstract |
|
|
dc.language.iso |
en |
|
dc.relation.ispartofseries |
The Lancet |
|
dc.rights |
только для КФУ |
|
dc.subject |
diabetes 1 type |
|
dc.title |
Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial |
|
dc.type |
Article |
|
dc.contributor.org |
Институт фундаментальной медицины и биологии |
|
dc.description.pages |
212-224 |
|
dc.relation.ispartofseries-issue |
9 |
|
dc.pub-id |
251429 |
|
dc.identifier.doi |
10.1016/ S2213-8587(21)00019-X |
|